Is The Malaria Parasite The Cancer Cure We’ve Been Looking For? Accidental Discovery Displays Remarkable Results
The parasite that causes malaria may have a fortuitous side-effect.
NIAID CC BY 2.0
As far as accidents go, stumbling upon a potential cure for cancer is one we can all probably forgive. According to a recent study,
a group of Danish scientists might have done just that by discovering
that a potential malaria vaccine had the unexpected side effect of
killing tumors.
Malaria is bloodborne disease caused by the Plasmodium parasite. It is spread through humans by mosquito bites and, according to UNICEF, kills up to a million people each year. Malaria is especially dangerous for pregnant women as the parasite may attack the placenta, which then puts the child’s life at risk. In their ongoing efforts to prevent these specific infections, scientists from the University of Denmark made a remarkable observation: Due to the similar characteristics between tumors and placentas, the same technique malaria uses to attack and destroy placentas could also be used to destroy cancer tumors.
“The placenta is an organ, which within a few months grows from only few cells into an organ weighing approximately 2 pounds, and it provides the embryo with oxygen and nourishment in a relatively foreign environment,” study author Ali Salanti said in a statement. “In a manner of speaking, tumors do much the same — they grow aggressively in a relatively foreign environment."
The researchers attempted to improve on this natural design by attaching a cancer-killing toxin to the malaria protein. They found that the combination was lethal; in lab tests, it was up to 90 percent effective in destroying various cancer samples. The lethal combination was also tested successfully in mice that were implanted with different types of human cancers. And while it may seem jarring to trade off cancer for malaria, Thomas Mandel Clausen, a PhD student involved with the research, explained that the the malaria protein only attaches to the tumor “without any significant attachment to other tissue.”
It will be at least four years before the treatment will be available for human testing, and researchers are hopeful it’ll be a significant step forward in cancer treatment research. However, since the protein they use attaches to carbohydrates found only in the placenta and cancer tumors, this life-saving characteristic will make the treatment too dangerous for cancer treatment in pregnant women. “Expressed in popular terms, the toxin will believe that the placenta is a tumor and kill it, in exactly the same way it will believe that a tumor is a placenta,” Salanti said.
Source: Salani A, Clausen, Agerbæk M Ø, et al. Targeting Human Cancer by a Glycosaminoglycan Binding Malaria Protein. Cancer Cell. 2015
Malaria is bloodborne disease caused by the Plasmodium parasite. It is spread through humans by mosquito bites and, according to UNICEF, kills up to a million people each year. Malaria is especially dangerous for pregnant women as the parasite may attack the placenta, which then puts the child’s life at risk. In their ongoing efforts to prevent these specific infections, scientists from the University of Denmark made a remarkable observation: Due to the similar characteristics between tumors and placentas, the same technique malaria uses to attack and destroy placentas could also be used to destroy cancer tumors.
“The placenta is an organ, which within a few months grows from only few cells into an organ weighing approximately 2 pounds, and it provides the embryo with oxygen and nourishment in a relatively foreign environment,” study author Ali Salanti said in a statement. “In a manner of speaking, tumors do much the same — they grow aggressively in a relatively foreign environment."
The researchers attempted to improve on this natural design by attaching a cancer-killing toxin to the malaria protein. They found that the combination was lethal; in lab tests, it was up to 90 percent effective in destroying various cancer samples. The lethal combination was also tested successfully in mice that were implanted with different types of human cancers. And while it may seem jarring to trade off cancer for malaria, Thomas Mandel Clausen, a PhD student involved with the research, explained that the the malaria protein only attaches to the tumor “without any significant attachment to other tissue.”
It will be at least four years before the treatment will be available for human testing, and researchers are hopeful it’ll be a significant step forward in cancer treatment research. However, since the protein they use attaches to carbohydrates found only in the placenta and cancer tumors, this life-saving characteristic will make the treatment too dangerous for cancer treatment in pregnant women. “Expressed in popular terms, the toxin will believe that the placenta is a tumor and kill it, in exactly the same way it will believe that a tumor is a placenta,” Salanti said.
Source: Salani A, Clausen, Agerbæk M Ø, et al. Targeting Human Cancer by a Glycosaminoglycan Binding Malaria Protein. Cancer Cell. 2015
No comments:
Post a Comment